Company Profile
ABVC BioPharma, Inc. Stock Price, News & Analysis
- Ticker:
- ABVC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States and trades on NASDAQ, placing it in the small-cap biotech category
Stock performance
1.02 USD (+0.99%)
Close
Last updated: August 6, 2026
32.5M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ABVC closed up 0.99% at $1.02. No new same-company headline was identified in the current news window.
Company overview
Business overview
ABVC BioPharma is a small biotechnology company with programs spanning areas such as oncology, ophthalmology, and central nervous system health. Its profile is that of a micro-cap development company trying to create value through a mix of early-stage assets and licensing opportunities.
Geographic Base and Sector Classification
ABVC is headquartered in the United States and trades on NASDAQ, placing it in the small-cap biotech category. It is a development-stage name with limited commercial scale.
Business Model Characteristics
The business model depends on early clinical development, licensing, strategic partnerships, and financing discipline. Investors usually watch pipeline announcements, trial progress, and whether the company can sustain enough runway to advance its programs.
Position Within the Biotechnology Landscape
ABVC sits in the speculative micro-cap side of biotech. The stock is usually driven by announcements, capital structure, and the company's ability to maintain credibility across multiple early programs.
Future catalysts
ABVC BioPharma’s catalysts are its partnered clinical assets and any update that clarifies whether the company can still convert the pipeline into a viable path. The market will care about concrete progress rather than broad promises.
Recent news
- 01
- 02
- 03
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
Source: ABVC BioPharma, Inc.
- 04
- 05
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
Source: ABVC BioPharma, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ABVC BioPharma, Inc. (ABVC)?
ABVC BioPharma, Inc. (ABVC) most recently closed at 1.02 USD, a +0.99% move versus the previous session.
What is the market cap of ABVC BioPharma, Inc. (ABVC)?
ABVC BioPharma, Inc. currently has a market capitalization of 32.5M USD on BioPharmSignal.
What does ABVC BioPharma, Inc. do?
ABVC BioPharma is a small biotechnology company with programs spanning areas such as oncology, ophthalmology, and central nervous system health. Its profile is that of a micro-cap development company trying to create value through a mix of early-stage assets and licensing opportunities.
On which exchange is ABVC stock listed?
ABVC BioPharma, Inc. (ABVC) is associated with NASDAQ, United States and trades on NASDAQ, placing it in the small-cap biotech category, Biopharma.
What is BioPharma?
ABVC BioPharma’s catalysts are its partnered clinical assets and any update that clarifies whether the company can still convert the pipeline into a viable path.
Which conditions is ABVC BioPharma, Inc. targeting with BioPharma?
ABVC BioPharma, Inc. is associated with oncology, ophthalmology based on its company overview and current catalyst commentary.
How does ABVC BioPharma, Inc. describe recent progress with BioPharma?
ABVC BioPharma’s catalysts are its partnered clinical assets and any update that clarifies whether the company can still convert the pipeline into a viable path.
What future catalysts are investors watching for ABVC BioPharma, Inc.?
ABVC BioPharma’s catalysts are its partnered clinical assets and any update that clarifies whether the company can still convert the pipeline into a viable path. The market will care about concrete progress rather than broad promises.